Category: Automation and High-Throughput Technologies

1188-D - Robustness of HTRF PD1/PDL1 Blocker Assay on Apricot Designs S2 Pipette

Tuesday, February 6, 2018
5:00 PM - 6:00 PM

The success of targeting immune checkpoint pathway is booming the research on screening checkpoint blockers, leading to a demand of increased throughput and consistency.  HTRF (Homogeneous Time-resolved Fluorescence) PD1/PDL1 Blocker Assay is a simple mix-and-read assay suitable for screening both small molecule and antibody blockers of PD1/PDL1 binding. In this study, we tested HTRF PD1/PDL1 Blocker Assay on Apricot Designs S2 Pipette to evaluate the gained value of liquid handing system.  The assay was performed in a total volume of 20 ul on HTRF 96 well low-volume assay plate by adding PDL1 protein, blocker, PD1 protein, and detection reagents in sequence.  Three independent experiments, i.e. two by Apricot S2 and one by manual operation, were conducted in parallel. The assay exhibited a large window of 13 in both S2 Pipette and manual operation.  Blocker potency was clearly distinguished by IC50s, the values of which were consistent in S2 and manual operations.  Compared with manual operation, Apricot S2 offered reduced intra- and inter-assay CVs, i.e. <5% in 23/24 sample wells.  The average Z factor in two experiments conducted by Apricot S2 was 0.90.  The study demonstrated excellent compatibility of Apricot Designs S2 Pipette and HTRF PD1/PDL1 Blocker Assay.  Working together, the system offered a robust platform to screen small molecule and antibody blockers of immune checkpoint proteins.

Bing Xie

Managing Director of Asia Pacific
Cisbio Bioassays
Shanghai, Shanghai, China (People's Republic)

Bing Xie received his Ph.D. in Molecular Medicine from Yale University, School of Medicine. He then served as a postdoctoral associate in Department of Pathology, Yale University. In 2002, he became Director of Biological Application at Agilix Corporation. In 2006, Dr. Xie joined PerkinElmer as Technical Leader, focusing on the development of multiplexing platform in quantitative proteomics as well as the technologies in cell signaling and HTS. Subsequently, he worked at Helix Therapeutics as Director of R&D. Since 2008, Dr. Xie was leading Scientific Consulting Team in Cisbio, US. In the beginning of 2010, he became Managing Director, Asia Pacific for Cisbio Bioassays. Starting from 2013-2015, Dr. Xie was the member of Asia Council of The Society for Laboratory Automation and Screening (SLAS). Now he serves as Vice Chair for Executive Committee of Sino Drug Discovery Association.